NR1H4 and cancer: The findings that HIF-1α enhances the hepatic inflammation, fibrosis and cancer, and that CDCA and FXR agonists improve liver function lead us to investigate whether CDCA and a FXR agonist inhibit HIF-1α function in liver cells.